CN105285986A - Health food or pharmaceutical composition comprising chestnut shell extract - Google Patents
Health food or pharmaceutical composition comprising chestnut shell extract Download PDFInfo
- Publication number
- CN105285986A CN105285986A CN201510750348.7A CN201510750348A CN105285986A CN 105285986 A CN105285986 A CN 105285986A CN 201510750348 A CN201510750348 A CN 201510750348A CN 105285986 A CN105285986 A CN 105285986A
- Authority
- CN
- China
- Prior art keywords
- chestnut
- chestnut shell
- skin
- shell extract
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001070941 Castanea Species 0.000 title claims abstract description 162
- 235000014036 Castanea Nutrition 0.000 title claims abstract description 162
- 239000000284 extract Substances 0.000 title claims abstract description 113
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 235000013402 health food Nutrition 0.000 title abstract description 8
- 208000003251 Pruritus Diseases 0.000 claims abstract description 89
- 230000000694 effects Effects 0.000 claims abstract description 40
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims abstract description 36
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims abstract description 33
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims description 56
- 235000001497 healthy food Nutrition 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 230000008591 skin barrier function Effects 0.000 claims description 16
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 208000012657 Atopic disease Diseases 0.000 claims description 9
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- 206010062016 Immunosuppression Diseases 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000002797 proteolythic effect Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000001034 Frostbite Diseases 0.000 claims description 2
- 206010027627 Miliaria Diseases 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 201000004169 miliaria rubra Diseases 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 206010033898 parapsoriasis Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 229910052567 struvite Inorganic materials 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 16
- 108010070503 PAR-2 Receptor Proteins 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 97
- 238000000034 method Methods 0.000 description 41
- 238000012360 testing method Methods 0.000 description 39
- 239000000469 ethanolic extract Substances 0.000 description 37
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 34
- 230000008569 process Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- 108010003179 seryl-leucyl-isoleucyl-glycyl-lysyl-valine Proteins 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 238000009472 formulation Methods 0.000 description 17
- 238000006748 scratching Methods 0.000 description 16
- 230000002393 scratching effect Effects 0.000 description 16
- CNOKQOBEMGIIAH-JYAZKYGWSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O CNOKQOBEMGIIAH-JYAZKYGWSA-N 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 108010014211 seryl-leucyl-isoleucyl-glycyl-arginyl-leucine Proteins 0.000 description 15
- 230000008859 change Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 108090001007 Interleukin-8 Proteins 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 12
- 229940100601 interleukin-6 Drugs 0.000 description 12
- 229940096397 interleukin-8 Drugs 0.000 description 12
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 235000019437 butane-1,3-diol Nutrition 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000001387 anti-histamine Effects 0.000 description 8
- 239000000739 antihistaminic agent Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 6
- 102000004125 Interleukin-1alpha Human genes 0.000 description 6
- 108010082786 Interleukin-1alpha Proteins 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000028990 Skin injury Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 230000001329 hyperkeratotic effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- COPBKCYMXSUALT-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound O=C1NC=CO1.O=C1NC=CO1 COPBKCYMXSUALT-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 240000004957 Castanea mollissima Species 0.000 description 1
- 235000018244 Castanea mollissima Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101001098561 Mus musculus Proteinase-activated receptor 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 201000002463 atopic dermatitis 2 Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a health food or pharmaceutical composition for alleviating or suppressing pruritus, comprising chestnut shell extract as an active ingredient. In one example of the present invention, the chestnut shell extract comprised in the health food or pharmaceutical composition of the present invention can suitably be used as the active ingredient of a health food or pharmaceutical composition for alleviating or suppressing pruritus as it has been confirmed that it can exhibit an outstanding effect in alleviating or suppressing pruritus by suppressing the activity of -2(proteinase-activated receptor-2:PAR-2) which is a source of stimulation in pruritus.
Description
Patent application of the present invention is the divisional application proposed for the application that the applying date is on 06 18th, 2010, application number is 201080035903.3, denomination of invention is " healthy food containing chestnut shell extract or pharmaceutical compositions ".
Technical field
The present invention relates to the healthy food containing chestnut shell extract or pharmaceutical compositions.
Background technology
Itch is defined as bringing out the offending dermal sensation of the desire wanting to scratch; as pain, sense of touch, cold or hot and so on physiological defence mechanism; time in the destructive stimulus that skin is exposed to from outside, cognition is carried out to it and plays the effect protecting skin.
Pruritus is the one in the common symptoms of often performance in various skin disease or general disease, actual conditions are, nettle rash, severe pruritus disease caused by various side effects of pharmaceutical drugs can easily be cured, but the treatment of the chronic pruritus of the severe of Biliary atresia, kidney trouble or atopic diseases and so on is very difficult.
Itch is brought out by many reasons such as inflammation, cancer, metabolic disease, infection, psychiatric condition, drug administration or pressure, in nearest some results of study, specify that skin and peripheral nervous system and central nervous system organic be connected with for bring out itch stimulation reaction, regulate closely related.
Recently, specify that specific sensory neurone and acceptor thereof react specifically to itch, receive the next state that itch is not pain, but as indivedual sensations of sensory nervous system, think mutually different itch medium and acceptor thereof and multiple disease association (Steinhoffetal., JournalofInvestigativeDermatology, 126 of bringing out itch, pp1705-1718,2006).
In the experiment for pruritus research up to now, main use histamine, but following opinion is proposed, namely the chronic pruritus of idiocrasy and so on is caused by histamine dependence path (pathway), not equal to be caused by nerve reason, this is illustrated as the pruritus not onset (Standeretal. of what antihistamine to atopic diseases, ExperimentalDermatology, 11, pp12-24,2002).
In addition, known 1st generation antihistaminic is mainly used in Formulations for systemic administration, but there is anti-parasympathetic effect and show sedation, as the antihistaminic chlorpheniramine of 1st generation when topical, the itch (Mundayetal. of atopic dermatitis patients cannot be suppressed, Dermatology, 205, pp40-45,2002), owing to there is the danger of cutaneous anaphylaxis, therefore do not encourage to use topical anti-histamines to atopic dermatitis.As when taking together with the medicine not having the antihistaminic Ebastine of contrastimulant 2nd generation, RMI 9918 with block cell pigment (cytochrome) P450 activity (ketoconazole, erythromycin), sometimes cardiac arrhythmia (Heyetal. is caused, Arzneimittelforschung, 46, pp159-163,1996), relative side effect is caused.
Therefore, at present in the urgent need to exploitation at the little and pruritus therapeutic agent of safety of effective side effect simultaneously, particularly to the effective curative of chronic pruritus of idiocrasy and so on.
Summary of the invention
Therefore, the object of the invention is to solve technical task to be solved all the time.Specifically, the object of one embodiment of the present of invention be to provide containing chestnut shell extract for relaxing or suppressing the healthy food of pruritus or pharmaceutical compositions, for improving the healthy food of skin barrier or pharmaceutical compositions and for the healthy food of Immunosuppression or pharmaceutical compositions.
According to such object, one embodiment of the invention relates to containing healthy food or the pharmaceutical compositions for relax or suppress pruritus of chestnut shell extract as active ingredient, and it had not only reduced side effect that pruritus curative in the past has, but also the effect having excellent suppression or relax pruritus.
One embodiment of the invention relates to containing healthy food or the pharmaceutical compositions for improve skin barrier function of chestnut shell extract as active ingredient.
One embodiment of the invention relates to containing chestnut shell extract as the healthy food for Immunosuppression of active ingredient or pharmaceutical compositions.
One embodiment of the present of invention relate to containing healthy food or the pharmaceutical compositions for improve or treat atopic dermatitis of chestnut shell extract as active ingredient.
Composition of the present invention contains chestnut shell extract as active ingredient, thus excellent pruritus suppression or alleviation effects is played by suppressing the activity as the proteolytic activity acceptor-2 (Proteinase-ActivatedReceptor-2:PAR-2) of itch stimulus, not only can improve the Skin barrier destruction brought out by pruritus significantly, but also can be treated to essence the immune hypersensitivity reaction that can become the reason of bringing out pruritus by the immunosuppressive activity of chestnut shell extract.
Accompanying drawing explanation
Fig. 1 is the chart of the measurement result of the active inhibition (trypsin treatment) of PAR-2 of the chestnut shell extract that one embodiment of the present of invention are shown.
Fig. 2 is the chart of the measurement result of the active inhibition (SLIGKV process) of PAR-2 of the chestnut shell extract that one embodiment of the present of invention are shown.
Fig. 3 is the chart of the measurement result of the active inhibition (trypsase, SLIGKV process) of PAR-2 of chestnut skin 1,3-BDO (BG) extract that one embodiment of the present of invention are shown.
Fig. 4 is the chart of pruritus (trypsin treatment) inhibition of chestnut skin 1,3-BDO (BG) extract that one embodiment of the present of invention are shown.
Fig. 5 is the chart of pruritus (SLIGRL process) inhibition of chestnut skin 1,3-BDO (BG) extract that one embodiment of the present of invention are shown.
Fig. 6 is the chart of pruritus (SLIGRL process) inhibition of the chestnut skin ethanol extract that one embodiment of the present of invention are shown.
Fig. 7 is the chart of pruritus (SLIGRL process) inhibition of the chestnut skin ethanol extract oral administration that one embodiment of the present of invention are shown.
Fig. 8 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect of TNF-α secretion.
Fig. 9 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect of IL-6 secretion.
Figure 10 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect of IL-1 α secretion.
Figure 11 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect of IL-8 secretion.
Figure 12 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect of GM-CSF secretion.
Figure 13 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect that IL-6 secretes caused by trypsase and active peptide (SLIGKV).
Figure 14 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect that IL-8 secretes caused by trypsase and active peptide (SLIGKV).
Figure 15 illustrates that the chestnut shell extract of one embodiment of the present of invention reduces the chart of the effect that GM-CSF secretes caused by trypsase and active peptide (SLIGKV).
Figure 16 is the chart of the measurement result of the skin moisturization of the chestnut skin ethanol extract that one embodiment of the present of invention are shown.
Figure 17 is the chart of the measurement result of the hyperkeratotic effect of improvement of the chestnut skin ethanol extract that one embodiment of the present of invention are shown.
Figure 18 illustrates that the pruritus of chestnut skin ethanol extract in NC/Nga model of one embodiment of the invention improves the chart of the measurement result of effect.
Figure 19 illustrates that the IgE of the chestnut skin ethanol extract of one embodiment of the invention in NC/Nga model reduces the chart of the measurement result of effect.
Figure 20 is the chart of the measurement result of the active inhibition of PAR-2 that the endothelium (tender skin) of the chestnut that one embodiment of the present of invention are shown and crust (shell) extract cause.
Detailed description of the invention
The present invention relates to containing healthy food or the pharmaceutical compositions for relax or suppress pruritus of chestnut shell extract as active ingredient.The target that proteolytic activity acceptor-2 (Proteinase-ActivatedReceptor-2:PAR-2) is treated as pruritus by present inventor etc., measure the degree of the PAR-2 activity suppression that chestnut shell extract causes, result as in aftermentioned embodiment confirm, confirm to demonstrate excellent PAR-2 antagonism in vitro, in addition, at the SLIGRL as the peptide making PAR-2 activate specifically, in SLIGKV or the itch Inhibition test that brings out as the trypsase (Trypsin) of protease, confirm the activity suppressing PAR-2 significantly, show very excellent itch inhibition.
Above-mentioned pruritus is also referred to as pruritus, induced factor or the form of this pruritus are not particularly limited, such as, by comprising struvite dermatitis, atopic dermatitis, skin chap in the dermatitis of caused dermatitis, prickly heat, ulcer, frostbite, contact dermatitis, seborrhea, psoriasis and parapsoriasis more than one bring out.
When pruritus, can wipe skin constantly due to continuity itch, scratch or pinch.Thus, bring out the Secondary skin injuries such as the ulcer of skin, scratch, lichen, pruigo, hyperpigmentation or pigmentation minimizing, the various materials of inflammatory reaction in secretion induced skin, such secretion increases itch again, and forms the circulation of itch-scratch.
But chestnut shell extract contained in healthy food of the present invention or pharmaceutical compositions shows effective skin barrier function and improves effect, and the Secondary skin injury that itch is brought out can be prevented or treat to result effectively.
Above-mentioned composition in the damage of mitigation skin barrier or improve in skin barrier restoring force and show significant effect, thus, can improve skin barrier to such as produced by the itch from atopic dermatitis 2 property skin injuries significantly.
Particularly, above-mentioned composition can by promoting skin moisture-keeping, preventing hyperkeratosis and improve skin barrier, and as confirmed by aftermentioned embodiment, present inventor etc. utilize and use hairless mouse (Hairlessmice)
the allergic model that oxazolone (oxazolon) carries out processing is tested, measure through transepidermal water loss (transepidermalwaterloss, TEWL) and skin thickness (skinthickness), chestnut shell extract display is effective promotes skin moisture-keeping or prevent its hyperkeratotic effect for results verification.
And then, the present invention relates to containing chestnut shell extract as the healthy food for Immunosuppression of active ingredient or pharmaceutical compositions.Above-mentioned composition can be used for the treatment of such as idiocrasy, the healthy food of rheumatoid arthritis (rheumatoidarthritis) or Crohn disease (Crohn ' sdisease) or pharmaceutical compositions, wherein, can be for preventing or treating the composition of atopic diseases as immune hypersensitivity reaction.
When atopic diseases is from the acute phase that skin injury etc. causes to chronic disease stage development, observe the change of the multiple secretor state of immune mediator, but in the injured skin of patient suffering from atopic diseases, the concentration of most interleukins (Interleukin) becomes increase.In addition, granulocyte-macrophage colony stimutaing factor (GM-CSF) is known in the injured skin of atopical skin Disease, its secretory volume increases, cause chronic inflammatory reaction, and unbalanced (Matsubaraetal., FEBSLetters, 566 of idiocrasy patient immune system can be caused, pp195-200,2004).
Related to this, present inventors etc. confirm chestnut shell extract and significantly can reduce and react relevant tumor necrosis factor-alpha (TumorNecrosisFactor-α: TNF-α) to immune hypersensitivity, interleukin-6 (IL-6), interleukin-1 alpha (IL-1 α), the expression of interleukin 8 (IL-8) or granulocyte-macrophage colony stimutaing factor (Granulocyte-MacrophageColonyStimulatingFactor:GM-CSF), result chestnut shell extract is suitable for as the healthy food of Immunosuppression or the active ingredient of pharmaceutical compositions.
Particularly, the present invention contains chestnut shell extract as active ingredient, is suitable for the active ingredient of the cosmetic combination improving or treat atopic dermatitis.
In addition, above-mentioned interleukin-6 (IL-6) and interleukin 8 (IL-8) also by known be the factor of bringing out itch in atopic diseases, chestnut shell extract can prevent for the pruritus of prevention and therapy from atopic diseases effectively.
Above-mentioned chestnut skin refers to the dark brown skin covering chestnut tree fruit, and the chestnut shell extract used in this description refers to more than one the extract in the endothelium (tender skin), crust and composition thereof being selected from chestnut.
Above-mentioned chestnut micromicro is with the skin being chestnut from arbitrary kind, be not particularly limited, can be such as be selected from chestnut (CastaneacrenataS.etZ., CastaneamollissimaBl., Castaneabulgaris), the skin of more than one chestnut in Chinese chestnut (CastaneaBungeanaBl.) and Korea's chestnut (Castaneacrenatafor.multicarpa (Uyeki) Chung).As chestnut skin, the endothelium of chestnut (tender skin) can be used, also can use the crust (shell) of chestnut, but confirm especially to present excellent PAR-2 antagonism in the group through chestnut crust (shell) extract-treated.
The extracting method of above-mentioned chestnut shell extract is not particularly limited, such as can by being selected from water, carbon number is the lower alcohol of 1 ~ 4, 1, more than one solvents in 3-butanediol and mixed solvent thereof extract, above-mentioned solvent can be such as be selected from water, methyl alcohol, ethanol, 1, 3-butanediol, more than one in butanols and composition thereof, such as, above-mentioned chestnut shell extract can by the alcohol solution of 10 ~ 100% or 10 ~ 100% 1, 3-butanediol extracts, specifically, it can be 20 ~ 90% ethanol water solution extracts of chestnut skin or 10 ~ 70% 1, 3-butanediol extract, more specifically, it can be 40 ~ 90% ethanol water solution extracts of chestnut skin or 10 ~ 50% 1, 3-butanediol extract, more specifically, it can be 60 ~ 90% ethanol water solution extracts of chestnut skin or 20 ~ 40% 1, 3-butanediol extract.
The content of chestnut shell extract contained in above-mentioned composition is not particularly limited, but with the gross weight of composition for benchmark, can contain with the content of 0.005 ~ 80 % by weight, preferably can contain with 0.01 ~ 30 % by weight.If the content of above-mentioned chestnut shell extract is very few, then effect becomes very micro-, if too much, then the stability of formulation can step-down.
According to circumstances, in order to relax or suppress pruritus, improve skin barrier and Immunosuppression, chestnut shell extract also can be used with one or more the material in antihistaminic, steroid dose, local anesthetic, immunodepressant.
In the past, take antihistaminic, anabolic agent is coated with as external preparation for relaxing the technology of atopic dermatitis and pruritus, even if but these preparations have and present temporary transient result for the treatment of and also recur such shortcoming very soon, and then, report the side effect such as central nervous disorders when taking these medicines, digestive organs obstacle.As the anabolic agent of cortex hormone of aadrenaline due to efficient antiinflammation and immunosuppressive action and excellent effect, but side effect is also serious, the treatment of tacrolimus hydrate ointment to atopic dermatitis reported as immunodepressant is effective, but may cutaneum carcinoma be brought out, or bring out nephropathy when skin lesion sites absorbs in body in a large number, actual conditions consider in security, is difficult to Long-Time Service.
Therefore, using containing chestnut shell extract as one or more in the composition of active ingredient and antihistaminic, steroid dose, local anesthetic, immunodepressant suitably and the used time, can improve the mitigation of pruritus or suppression, skin barrier and immunosupress etc. show significant effect safely without side effect.
Above-mentioned pharmaceutical compositions can also contain anticorrisive agent, stabilizing agent, hydrating agents or emulsification promoter, further for regulating the pharmaceutic adjuvants such as the salt of osmotic pressure and/or buffer and other materials useful in treatment, except conventional inorganic or organic carrier, oral administration can also be carried out with solid, semisolid or aqueous form, or with parenteral, rectum, locally, in skin, intravenous, muscle, in abdominal cavity, subcutaneous etc. carry out administration, particularly preferably oral administration.
Above-mentioned oral Preparation has such as tablet, pill, hard and soft capsules, liquid preparation, suspending agent, emulsion, syrup, granule etc., and these formulations can also contain diluent (example: lactose, glucose, sucrose, sweet mellow wine, D-sorbite, cellulose and glycine), lubricant (example: silica, talcum, stearic acid and magnesium thereof or calcium salt and polyethylene glycol) except active ingredient.Tablet can also contain the bonding agent of Magnesiumaluminumsilicate, gelatinized corn starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone and so on, according to circumstances, the pharmacy additives such as the disintegrant of starch, agar, alginic acid or its sodium salt and so on, absorbent, colouring agent, flavouring agent and sweetener can be contained.Above-mentioned tablet can be prepared by common mixing, granulating or coating process.
In addition, above-mentioned non-oral administration agent can be such as skin preparations for extenal use, also can be the formulation of lotion, ointment, gel, frost, patch or spray, but be not limited to these.
Above-mentioned health food composition is not particularly limited formulation, such as, can make the formulations such as tablet, granule, potus, molasses, meal rod (dietbar).To the health food composition of each formulation, except active ingredient, those skilled in the art can coordinate suitably selected according to formulation or application target for normally used for this field composition without difficulty, when using with other raw material, can play synergy simultaneously.
The dosage of above-mentioned active ingredient fixes in the level of those skilled in the art really, administration consumption on the 1st of medicine is different according to the many factors such as progress extent, occurrent time, age, health status, the complication difference of object to be administered, if but be benchmark with adult, then generally above-mentioned composition 1 ~ 500mg/kg, preferably 30 ~ 200mg/kg can be divided into 1 ~ 2 time according to 1 day and carry out administration, no matter above-mentioned dosage does not limit scope of the present invention by any method yet.
Below, further describe the present invention by embodiment, but following embodiment is for illustrating the present invention, scope of the present invention not limit by them.
The preparation of [embodiment 1] chestnut shell extract
1-1) the preparation of chestnut skin 1,3-BDO extract
Utilize the 1,3-BDO (1,3-buthyleneglycol) of 30%, make chestnut skin at room temperature leach 3 days.Then, filter successively with the filter of 250 orders, 3 μm, 1 μm, 0.5 μm sizes.Then, at 0 ~ 4 DEG C, place (Standing) after 3 days, filter successively with the filter of 0.5 μm, 0.3 μm, 0.2 μm size, obtain chestnut skin 1,3-BDO extract.
1-2) the preparation of chestnut skin ethanol extract
Utilize 70% ethanol, make chestnut skin at room temperature leach 3 days.Then, filter successively with the filter of 250 orders, 3 μm, 1 μm, 0.5 μm, 0.3 μm, 0.2 μm sizes.Then, at 60 DEG C after concentrated solution, at 30 DEG C, implement the vacuum drying of 18 hours, obtain the chestnut skin ethanol extract of powder morphology.
The active inhibition (external, trypsin treatment, HEK: people's epidermal keratinocyte) of PAR-2 of [test example 1] chestnut skin ethanol extract
Experiment the previous day, by keratinocyte (cell line name: HaCaT, obtain place: ATCC) in 96 holes (well) plate to become 4 × 10
4the mode of cells/well carries out plant division, then at 37 DEG C, 5%CO
2incubator (incubator) in cultivate 24 hours.After 24 hours, by 96 orifice plates with after HBSS (Hanks ' BalancedSaltsolution) buffer solution for cleaning (washing) 2 times, by reaction buffer (reactionbuffer:2uMFluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) add in cell.At 37 DEG C, 5%CO
2incubator (incubator) in reaction 30 minutes, at room temperature react after 30 minutes, by HBSS buffer solution for cleaning (washing) 2 times, chestnut skin ethanol extract is processed with the concentration versus cell of 1ppm, 2ppm, 5ppm, 10ppm, 20ppm, 30ppm and 50ppm respectively.React after 10 minutes, process with 2U/ml trypsase (Trypsin), Ca in the cell measuring for 80 seconds
2+change in concentration.Ca in cell
2+the mensuration of change in concentration utilizes FlexStation3 (molecular device, the U.S.).After chestnut skin ethanol extract and trypsase (Trypsin) process, obtain the flexing (flex) in mensuration 80 second and after the difference of the minimum of a value in the value obtained and maximum, minimum of a value when this value and trypsase (Trypsin) being processed and the difference of maximum compare and obtain inhibiting rate.
With reference to Fig. 1, when can confirm to utilize trypsase at N-end cutting filament amino acid sequence (sequence) of PAR-2, PAR-2 to be activated, calcium ion flows in cell, but through the group of chestnut shell extract process when, PAR-2 activation is suppressed, and the inflow of calcium ion significantly reduces.
The active inhibition (external, SLIGKV process, HEK: people's epidermal keratinocyte) of PAR-2 of [test example 2] chestnut skin ethanol extract
Experiment the previous day, by keratinocyte (cell line name: HaCaT, obtain place: ATCC) in 96 holes (well) plate to become 4 × 10
4the mode of cells/well carries out plant division, then at 37 DEG C, 5%CO
2incubator (incubator) in cultivate 24 hours.After 24 hours, by 96 orifice plates with after HBSS (Hanks ' BalancedSaltsolution) buffer solution for cleaning (washing) 2 times, by reaction buffer (reactionbuffer:2uMFluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) add in cell.At 37 DEG C, 5%CO
2incubator (incubator) in reaction 30 minutes, at room temperature react after 30 minutes, by HBSS buffer solution for cleaning (washing) 2 times, chestnut skin ethanol extract is processed with the concentration versus cell of 1ppm, 2ppm, 5ppm, 10ppm, 20ppm, 30ppm and 50ppm respectively.React after 10 minutes, process with 5uMPAR-AP (SLIGKV), Ca in the cell measuring for 80 seconds
2+change in concentration.Ca in cell
2+the mensuration of change in concentration utilizes FlexStation3 (molecular device, the U.S.).After chestnut skin ethanol extract and 5uMPAR-AP (SLIGKV) process, obtain the flexing (flex) in mensuration 80 second and after the difference of the minimum of a value in the value obtained and maximum, minimum of a value when this value and 5uMPAR-AP (SLIGKV) being processed and the difference of maximum compare and obtain inhibiting rate.
With reference to Fig. 2, can confirm if the SLIGKV (people) belonging to activated peptide plays a role as direct part and makes PAR-2 activate, then flow into calcium ion in cell, but through the group of chestnut shell extract process when, PAR-2 activation is suppressed, and the inflow of calcium ion significantly reduces.
The active inhibition (external, SLIGKV process, HEK: people's epidermal keratinocyte) of PAR-2 of [test example 3] chestnut skin 1,3-BDO (BG) extract
Experiment the previous day, by keratinocyte (cell line name: HaCaT, obtain place: ATCC) in 96 holes (well) plate to become 4 × 10
4the mode of cells/well carries out plant division, then at 37 DEG C, 5%CO
2incubator (incubator) in cultivate 24 hours.After 24 hours, by 96 orifice plates with after HBSS (Hanks ' BalancedSaltsolution) buffer solution for cleaning (washing) 2 times, by reaction buffer (reactionbuffer:2uMFluo-4-AM, 20%Pluronic acid, 2.5mM probenecid) add in cell.At 37 DEG C, 5%CO
2incubator (incubator) in reaction 30 minutes, at room temperature react after 30 minutes, by HBSS buffer solution for cleaning (washing) 2 times, chestnut skin 1,3-BDO (BG) extract is processed with the concentration versus cell of 0.1w/v%, 0.5w/v% and 1w/v% respectively.React after 10 minutes, process with 2U/ml trypsase (Trypsin) or 5uMPAR-AP (SLIGKV), Ca in the cell measuring for 80 seconds
2+change in concentration.Ca in cell
2+the mensuration of change in concentration utilizes FlexStation3 (MolecularDevice, USA).Through chestnut skin 1, after 3-butanediol (BG) extract and 2U/ml trypsase (Trypsin) or 5uMPAR-AP (SLIGKV) process, after obtaining the difference of the flexing (flex) in mensuration 80 second and the minimum of a value in the value that obtains and maximum, the difference of this value and the minimum of a value when 2U/ml trypsase or 5uMPAR-AP (SLIGKV) process and maximum is compared and obtains inhibiting rate.
With reference to Fig. 3, can confirm that the inflow of the intracellular calcium that trypsase or PAR-2 active peptide (SLIGKV) cause uprises along with the concentration of chestnut shell extract and significantly reduces.
[test example 4] chestnut skin 1,3-BDO (BG) extract is to the inhibition of the pruritus brought out by trypsase
Observe in hairless mouse (Hairlessmice), by chestnut skin 1,3-butanediol (BG) extract (in PBS buffer solution) injects with the concentration of 1w/v%, 10w/v% and 20w/v% respectively simultaneously, and the behavioral trait of scratching (scratchingbehavior) that intracutaneous (ID) is injected caused by trypsase (in PBS buffer solution) 200 μ g/ position is suppressed by concentration.Each measured value represents with the percentage change measuring mean value relative to 2 baselines (Baseline), the results are shown in Fig. 4.
With reference to Fig. 4,1,3-BDO (BG; Carrier) disposal group and 1% chestnut skin 1,3-butanediol (BG) extract disposal group is observed the effect not having to suppress the itch of being brought out by trypsase, but it is very large to observe inhibition in 10%, 20% chestnut skin 1,3-BDO (BG) extract disposal group.
[test example 5] chestnut skin 1,3-BDO (BG) extract is to the inhibition of the itch of being brought out by SLIGRL
Observe in hairless mouse (Hairlessmice), by chestnut skin 1,3-butanediol (BG) extract (in PBS buffer solution) injects with the concentration of 1%, 10% and 20% respectively simultaneously, and the behavioral trait of scratching (scratchingbehavior) making intracutaneous (ID) inject caused by SLIGRL (mouse PAR-2 active peptide, in PBS buffer solution) 50 μ g/ position is suppressed by concentration.Each measured value percentage change measuring mean value relative to 2 baselines (Baseline) represents, the results are shown in Fig. 5.
With reference to Fig. 5, can observe from 1% chestnut skin 1,3-butanediol (BG) extract disposal group starts to 10%, 20% chestnut skin 1,3-butanediol (BG) extract disposal group, along with the concentration of chestnut shell extract increases, the degree that the itch of being brought out by SLIGRL is suppressed increases.
The effect of the pruritus that the suppression that the skin application of [test example 6] chestnut skin ethanol extract causes is brought out by SLIGRL
The chestnut shell extract each test group being carried out to skin application process is all be dissolved in water, ethanol, 1,3 butanediols carry out with the ratio of 5:3:2 in the solution mixed and use, and experimental concentration is used with the concentration of 1,3 and 10w/v% by the chestnut skin ethanol extract of powder morphology.Carrier (vehicle) group uses the extract and the preparation that makes that do not add embodiment 1, as itch evocating substance, by PAR-2 active peptide (ActivatingPeptide (SLIGRL, peptide from rodent)) be dissolved in PBS buffer solution, carry out intracutaneous injection with the concentration at 50 μ g/ places.
Get each sample 200 μ l of chestnut skin ethanol extract, process in the mode extensively stretching coating at the position, back of hairless mouse.Be divided into the morning and afternoon, 1 day 2 times, process 4 days, the morning of the 5th day, before itch evocating substance injects 30 minutes, carry out last process.
In order to the presence or absence of the itch minimizing that the increase and chestnut skin ethanol extract of comparing the caused itch of itch evocating substance (PAR-2 active peptide, SLIGRL) cause, the skin application measuring chestnut skin ethanol extract measures the number of times of scratching of 40 minutes for first 2 days at every turn, the number of times of scratching that the value obtained by the calculating mean value of 2 days and stimulus inject latter 40 minutes compares, and represents with percent change value.
The experiment of itch loaded observation with in transparent hurdle giving 20 minutes adaptation times from by hairless mouse at injection itch evocating substance before 20 minutes.At the end of adaptation time, by itch evocating substance (PAR-2 active peptide; SLIGRL) intracutaneous injection (intradermalinjection) is carried out to the skin at the position, back adapting to the test hairless mouse terminated.At the end of injection, directly again loaded by hairless mouse after in observation hurdle, the hind leg measuring 40 minutes injection of scratching has the number of times at the position of itch evocating substance.The behavior of scratching with front foot or catch in its mouth is foreclosed, only the index of the behavior of injection site of scratching with metapedes as itch behavior is measured.
With reference to Fig. 6, after can confirming that chestnut skin ethanol extract (ChestnutInnerBarkExtract) is coated skin, when the concentration for 10%, even if do not giving under the usual state stimulated with itch, number of times of scratching also reduces, when give stimulates with itch, number of times of scratching from 1% concentration minimizing.
The effect of the pruritus that the suppression that the oral administration of [test example 7] chestnut skin ethanol extract causes is brought out by SLIGRL
The female hairless mice (Harilessmice) of extract to 8 week age obtained in embodiment 1 is carried out oral administration, observes itch inhibition.
Carry out chestnut shell extract equal the mixing with distilled water of oral administration process to each test group and use as suspension, experimental concentration is that the chestnut skin ethanol extract of powder morphology is carried out oral administration with the concentration of 200 and 500mg/Kg respectively.Carrier (vehicle) group is not added the extract of embodiment 1 and uses pure distilled water, as itch evocating substance, by PAR-2 active peptide (ActivatingPeptide (SLIGRL, peptide from rodent)) be dissolved in PBS buffer solution, carry out intracutaneous injection with the concentration at 50 μ g/ places.
Oral administration is the said sample of getting appropriate amount, with 1 administration on the 1st 5 days, the morning of the 5th day, before itch evocating substance injects 30 minutes, carries out last administration.
In order to the presence or absence of the itch minimizing that the increase and chestnut skin ethanol extract oral administration of comparing the caused itch of itch evocating substance (PAR-2 active peptide, SLIGRL) cause, the oral administration measuring chestnut skin ethanol extract measures the number of times of scratching of 40 minutes for first 2 days at every turn, the number of times of scratching that the value obtained by the calculating mean value of 2 days and stimulus inject latter 40 minutes compares, and represents with percent change value.
Itch experiment loaded observation with in transparent hurdle giving 20 minutes adaptation times from by hairless mouse at injection itch evocating substance before 20 minutes.After adaptation time terminates, by itch evocating substance (PAR-2 active peptide; SLIGRL) intracutaneous injection (intradermalinjection) is carried out to the skin at the position, back adapting to the test hairless mouse terminated.After injection terminates, directly hairless mouse is loaded again after in observation hurdle, measures 40 minutes scratch to inject with hind leg and have the number of times at the position of itch evocating substance.The behavior of scratching with front foot or catch in its mouth is foreclosed, only the index of the behavior of injection site of scratching with metapedes as itch behavior is measured.
With reference to Fig. 7, after can confirming that chestnut skin ethanol extract is carried out oral administration, chestnut skin reduces with concentration the inhibition that itch stimulates.
[test example 8] chestnut shell extract causes the secretion of TNF-α to reduce
Test the previous day, by Keratoderma epithelial cell (Normalhumanskinkeratinocyte, NHEK, distributors: Lonza) to become 5 × 10
4the mode of cells/well carries out plant division in 96 holes (well) plate, then at 37 DEG C, 5%CO
2incubator (incubator) in cultivate 24 hours.After 24 hours, clean 2 cells with PBS, change serum-free KBM (serumfreeKBM (keratinocyte hosqt media)) into.By concentration, (10,25,50ppm) are processed through chestnut skin to each hole (well), reacts after 30 minutes, use PGSA (10,50ppm), LPS (1ppm) process respectively.At 37 DEG C, 5%CO
2incubator (incubator) in cultivate after 24 hours, take out nutrient solution, carry out the ELISA to TNF-α.ELISA utilizes the experimental technique of manufacturing company (BDscience).
With reference to Fig. 8, the TNF-α secretion significantly minimizing that chestnut skin makes to increase because of PGSA and LPS can be observed.
[test example 9] chestnut shell extract causes the secretion of IL-6 to reduce
Carry out the ELISA to IL-6, in addition, utilize the method identical in fact with test example 8.
With reference to Fig. 9, the suppression that IL-6 secretion that chestnut skin makes to increase because of PGSA and LPS obtains great disparity can be observed.
[test example 10] chestnut shell extract causes the secretion of IL-1 α to reduce
Carry out the ELISA to IL-1 α, in addition, utilize the method identical in fact with test example 8.
With reference to Figure 10, can observe the IL-1 α secretory volume that chestnut skin makes to increase because of PGSA and LPS increases with concentration and reduces.
[test example 11] chestnut shell extract causes the secretion of IL-8 to reduce
Carry out the ELISA to IL-8, in addition, utilize the method identical in fact with test example 8.
With reference to Figure 11, the IL-8 secretion significantly minimizing that chestnut skin makes to increase because of PGSA and LPS can be observed.
[test example 12] chestnut shell extract causes the secretion of GM-CSF to reduce
Carry out the ELISA to GM-CSF, in addition, utilize the method identical in fact with test example 8.
With reference to Figure 12, the concentration can observed along with chestnut skin increases, and the amount of the GM-CSF secreted because of PGSA and LPS reduces.
The inhibition that [test example 13] chestnut shell extract is secreted trypsase and the caused IL-6 of active peptide (SLIGKV)
Test the previous day, by Keratoderma epithelial cell (Normalhumanskinkeratinocyte, NHEK obtain place: Lonza) to become 5 × 10
4the mode of cells/well carries out plant division in 96 holes (well) plate, then at 37 DEG C, 5%CO
2incubator (incubator) in cultivate 24 hours.After 24 hours, clean 2 cells with PBS, change serum-free KBM (serumfreeKBM (keratinocyte hosqt media)) into.With chestnut shell extract, by concentration, (10,50ppm) are processed to each hole (well), react after 30 minutes, use trypsase (10nM) or PAR-2 activated peptide (SLIGKV, 50uM) to process respectively.At 37 DEG C, 5%CO
2incubator (incubator) in cultivate after 24 hours, take out nutrient solution, carry out the ELISA to IL-6.ELISA utilizes the experimental technique of manufacturing company (BDscience).
Secrete with reference to Figure 13, the IL-6 suppressing while chestnut shell extract concentration dependent can be observed trypsase and active peptide (SLIGKV) to cause.
The inhibition that [test example 14] chestnut shell extract is secreted trypsase and the caused IL-8 of active peptide (SLIGKV)
Carry out the ELISA to IL-8, in addition, utilize the method identical in fact with test example 13.
Secrete with reference to Figure 14, the IL-8 suppressing while chestnut shell extract concentration dependent can be observed trypsase and active peptide (SLIGKV) to cause.
The inhibition that [test example 15] chestnut shell extract is secreted trypsase and the caused GM-CSF of active peptide (SLIGKV)
Carry out the ELISA to GM-CSF, in addition, utilize the method identical in fact with test example 13.
Secrete with reference to Figure 15, the GM-CSF suppressing while chestnut shell extract concentration dependent can be observed trypsase and active peptide (SLIGKV) to cause.
[test example 16] measures the skin moisturization of chestnut skin ethanol extract
The chestnut skin ethanol extract of Evaluation operation example 1 is to the skin barrier function recovery capability of long-time skin injury.First, 1 time is coated with through back (back) every day of the young hairless mouse (Orient, Korea S) of 7 ~ 8 weeks after birth
oxazolone (oxazolone), is periodically coated with 6 days, the skin barrier of animal used as test is sustained damage.Then, measure with atmidometer (Delfin, Finland) and divide loss amount (TransepidermalWaterLoss:TEWL) through the severe edema due to hypofunction of the spleen, display 50g/m per hour will be had
2animal used as test above through the skin of skin moisture loss divides into groups, by 1 and the chestnut shell extract of 5w/v% respectively with every 5cm
2skin area is the capacity of 100 μ l, every day 2 times, and continuously coating is after 10 days, determination experiment animal divide loss amount (TEWL) through the severe edema due to hypofunction of the spleen, the results are shown in Figure 16.
As shown in figure 16, known hairless mouse to be carried out
in the allergic model (Allergymodel) of oxazolone process, by coating chestnut shell extract, to by
what the dermatitis (atopic dermatitis, atopicdermatitis) of oxazolone induction and causing increased divides loss amount to have to make the barrier function of damage to recover through the severe edema due to hypofunction of the spleen and gets back to the function of normal skin.
[test example 17] measures chestnut skin ethanol extract and improves hyperkeratotic effect
In embodiment 1, the effect that chestnut skin ethanol extract improves hyperkeratosis is evaluated.First, 1 time is coated with through back (back) every day of the young hairless mouse (Orient, Korea S) of 7 ~ 8 weeks after birth
oxazolone (oxazolone), is periodically coated with 6 days, the skin barrier of animal used as test is sustained damage.Then, measure with atmidometer (Delfin, Finland) and divide loss amount (TransepidermalWaterLoss:TEWL) through the severe edema due to hypofunction of the spleen, display 50g/m per hour will be had
2animal used as test above through the skin of skin moisture loss divides into groups, by substances with every 5cm
2skin area is the capacity of 100 μ l, every day 2 times, continuous coating is after 10 days, about picking up the measurement site of back (back), (twofold is measured, two-foldingmeasurement), utilize micrometer (Mitsubishi, Japan) to measure skin thickness, the results are shown in Figure 17.
With reference to Figure 17, the powder by using chestnut shell extract can be confirmed, to by
the dermatitis that oxazolone (oxazolon) brings out and cause the skin thickness increased to demonstrate suppressing the effect of hyperkeratosis.
[test example 18] measures chestnut skin ethanol extract and in NC/Nga model, reduces IgE and improve the effect of pruritus
In embodiment 1, effect is improved by IgE minimizing and itch in the serum of NC/Nga mouse model evaluation chestnut skin ethanol extract.First, utilize shearing machine (clipper) to lose hair or feathers after birth through back (back) position of the young NC/Nga mouse of 7 ~ 8 weeks, the gross profit depilatory cream of remnants is removed completely.To the position, back of exposing and auricle position, Df (dust mite (dermatophagoidesfarinae)) 100mg was coated with 4 times with one week 2 times equably in 3 weeks, and brings out atopic diseases.After carrying out administration with 2 groups that chestnut shell extract to be divided into 100mg/kg and 250mg/kg for one week 5 times in 3 weeks, in order to measure pruritus, after NC/Nga mouse is loaded observation hurdle, be determined at the number of times at position, back of scratching with hind leg between 2 hours.The behavior of scratching with front foot or catch in its mouth is foreclosed, only the index of the behavior of scratching with metapedes as itch behavior is measured.The blood sample separation of serum be determined as from being undertaken taking a blood sample by eye socket veniplex of SERUM IgE, utilizes the OptIgE kit (OptIgEkit) of BD science (BDscience) implement ELISA and measure.Represent itch minimizing compared with non-process group in 250mg/kg administration group in Figure 18, with reference to Figure 19, the minimizing showing IgE in the administration group of 250mg/kg significantly can be confirmed.
Comparing (external, SLIGKV process, HEK: people's epidermal keratinocyte) of the active inhibition of PAR-2 of [test example 19] chestnut crust ethanol extract and chestnut endothelium ethanol extract
The crust of chestnut and endothelium are carried out being separated and after drying, according to embodiment 1-2) identical method prepares the outer bark extract of chestnut, in chestnut bark extract also according to embodiment 1-2) prepared by identical method.Use the method identical with test example 2 to measure the active inhibition of PAR-2 of chestnut crust ethanol extract and chestnut endothelium ethanol extract, and be shown in following table 2 and Figure 20.
Table 2
Comparing (external, SLIGKV process, HEK: people's epidermal keratinocyte) of the active inhibition of PAR-2 of [test example 20] chestnut crust ethanol extract and chestnut endothelium ethanol extract
The crust (shell) of chestnut and the concentration of endothelium (tender skin) extract are carried out process as described in Table 3, in addition, measure the active inhibition of PAR-2 according to the method identical with test example 19.
Table 3
Below, the formulation example of the present composition is described, pharmaceutical compositions or health food composition can be applied to various formulation, and this does not really want to limit the present invention, and just will illustrate the present invention.
Ointment in [formulation example 1] skin preparations for extenal use
According to the composition that following table 1 is recorded, prepare ointment by conventional method.
Table 1
| Gradation composition | Content (% by weight) |
| Embodiment 1 | 0.1 |
| Glycerine | 3.0 |
| Butanediol | 2.0 |
| Propane diols | 2.0 |
| Carboxyl ethylene polymer | 0.1 |
| PEG-12 nonylplenyl ether | 0.2 |
| Polysorbate 80 | 0.4 |
| Ethanol | 10.0 |
| Triethanolamine | 0.1 |
| Anticorrisive agent, pigment, spices | In right amount |
| Purified water | Surplus |
The preparation of [formulation example 2] powder
Embodiment 1.........................100mg
Lactose ... ... ... ... ... 100mg
Talcum ... ... ... ... ... 10mg
Grease ... ... ... ... ... 5mg
Mentioned component is mixed, is filled in sealed packet and prepares powder.
The preparation of [formulation example 3] tablet
Embodiment 1..........................50mg
Cornstarch ... ... ... ... 100mg
Lactose ... ... ... ... ... 100mg
Dolomol ... ... ... .2mg
Vitamin C ... ... ... ... .50mg
After mentioned component is mixed, carry out compressing tablet according to the method for preparing tablet thereof of routine and prepare tablet.
The preparation of [formulation example 4] capsule
Embodiment 1..........................50mg
Corn ... ... ... ... ..100mg
Lactose ... ... ... ... ... 100mg
Dolomol ... ... ... .2mg
Vitamin C ... ... ... ... .50mg
Serine ... ... ... ... ... 50mg
According to the capsule preparation method thereof of routine, mentioned component is mixed, be filled in gelatine capsule and prepare capsule.
The preparation of [formulation example 5] liquid preparation
Embodiment 1.........................100mg
Isomerized sugar ... ... ... ... ... 10g
Sweet mellow wine ... ... ... ... ..5g
Vitamin C ... ... ... ... .50mg
Serine ... ... ... ... ... 50mg
Grease ... ... ... ... ... appropriate
Purified water ... ... ... ... ... .. is appropriate
Utilize conventional liquid preparation preparation method to add various composition in purified water and make it to dissolve, after adding appropriate lemonene, after mixing mentioned component, add purified water, after overall adjustment to 100ml, be filled in brown bottle, carry out sterilizing, prepare liquid preparation.
The preparation of [formulation example 6] healthy food
Embodiment 1........................1000mg
Vitamin mixtures
Retinyl acetate ... ... ... ..70 μ g
Vitamin E ... ... ... ... 1.0mg
Vitamin B1 ... ... ... ... .0.13mg
Vitamin B2 ... ... ... ... .0.15mg
Vitamin B6 ... ... ... ... ..0.5mg
Vitamin B12 ... ... ... ... .0.2 μ g
Vitamin C ... ... ... ... .10mg
Biotin ... ... ... ... ..10 μ g
Niacinamide ... ... ... ... 1.7mg
Folic acid ... ... ... ... ... .50 μ g
Calcium pantothenate ... ... ... 0.5mg
Inanimate matter mixture
Ferrous sulfate ... ... ... ... ..1.75mg
Zinc oxide ... ... ... ... 0.82mg
Magnesium carbonate ... ... ... ..25.3mg
Potassium dihydrogen phosphate ... ... ... ... 15mg
Calcium monohydrogen phosphate ... ... ... ..55mg
Potassium citrate ... ... ... ... .90mg
Calcium carbonate ... ... ... ... .100mg
Magnesium chloride ... ... ... ..24.8mg
The ratio of components of the mixture of said vitamin and mineral matter carries out mixing composition by comparing the composition preferred embodiment being suitable for healthy food, but also its match ratio can be implemented modification arbitrarily, after mentioned component can being mixed by the healthy food preparation method of routine, prepare particle, utilize conventional method for the preparation of health food composition.
The preparation of [formulation example 7] healthy beverage
Embodiment 1........................1000mg
Citric acid ... ... ... ... 1000mg
Oligosaccharides ... ... ... ... ..100g
Plum concentrate ... ... ... ... ... 2g
Taurine ... ... ... ... ... .1g
It is overall after adding purified water ... ... ... ..900ml
After mixing mentioned component by the healthy beverage preparation method of routine, at 85 DEG C, agitating heating is after about 1 hour, filters the solution made, loads in 2 DEG C of containers of sterilizing, after sealing sterilizing, stored refrigerated, then for the preparation of healthy beverage composition of the present invention.
Ratio of components is suitable for having a liking for the composition preferred embodiment of beverage and carries out mixing by comparing and form, but also can the region such as stratum, demand country, use, national characteristic hobby degree and its match ratio is carried out modification arbitrarily according to demand.
Claims (13)
1. the purposes of chestnut shell extract in the healthy food preparing the activity suppressing PAR-2 and proteolytic activity acceptor-2 or pharmaceutical compositions,
Wherein, described chestnut shell extract is the outer bark extract of chestnut,
Wherein, with the cumulative volume of described composition for benchmark, contain the outer bark extract of described chestnut with the content of 0.5% to 20% (w/v%) by weight.
2. the purposes of chestnut shell extract according to claim 1, wherein, described composition relaxes or suppresses pruritus.
3. the purposes of chestnut shell extract according to claim 1, wherein, described composition relaxes or suppresses the pruritus that brought out by following at least one: struvite dermatitis, atopic dermatitis, skin are chapped caused dermatitis, prickly heat, ulcer, frostbite, contact dermatitis, seborrhea, psoriasis and parapsoriasis.
4. the purposes of chestnut shell extract according to claim 1, wherein, the pruritus that described composition relaxes or suppression is brought out by atopic dermatitis.
5. the purposes of chestnut shell extract according to claim 1, wherein, described composition is for improving skin barrier function.
6. the purposes of chestnut shell extract according to claim 5, wherein, described composition damages for the skin barrier relaxed from atopic dermatitis or improves the restoring force of skin barrier.
7. the purposes of chestnut shell extract according to claim 5, wherein, described composition is for promoting skin moisture-keeping or preventing hyperkeratosis.
8. the purposes of chestnut shell extract according to claim 1, wherein, described composition is used for Immunosuppression.
9. the purposes of chestnut shell extract according to claim 8, wherein, described composition is used for prevention or the treatment of atopic diseases.
10. the purposes of chestnut shell extract according to claim 8, wherein, described composition is used for atopic treatment.
The purposes of 11. chestnut shell extracts according to claim 1, wherein, described composition is used for improving or treatment atopic dermatitis.
The purposes of 12. chestnut shell extracts according to any one of claim 1 to 11, wherein, described chestnut shell extract be by being selected from water, carbon number is the lower alcohol of 1 ~ 4, more than one the solvent in 1,3-BDO and their mixed solvent carries out extracting.
The purposes of 13. chestnut shell extracts according to claim 12, wherein, described chestnut shell extract is undertaken extracting by more than one the solvent be selected from water, methyl alcohol, ethanol, butanols, 1,3-BDO and their mixture.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2009-0054579 | 2009-06-18 | ||
| KR20090054579 | 2009-06-18 | ||
| CN2010800359033A CN102458156A (en) | 2009-06-18 | 2010-06-18 | Health food or pharmaceutical composition comprising chestnut shell extract |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800359033A Division CN102458156A (en) | 2009-06-18 | 2010-06-18 | Health food or pharmaceutical composition comprising chestnut shell extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105285986A true CN105285986A (en) | 2016-02-03 |
Family
ID=43356951
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800359033A Pending CN102458156A (en) | 2009-06-18 | 2010-06-18 | Health food or pharmaceutical composition comprising chestnut shell extract |
| CN201510750348.7A Pending CN105285986A (en) | 2009-06-18 | 2010-06-18 | Health food or pharmaceutical composition comprising chestnut shell extract |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800359033A Pending CN102458156A (en) | 2009-06-18 | 2010-06-18 | Health food or pharmaceutical composition comprising chestnut shell extract |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2012530699A (en) |
| KR (1) | KR101338681B1 (en) |
| CN (2) | CN102458156A (en) |
| WO (1) | WO2010147440A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3246B1 (en) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
| KR101595959B1 (en) * | 2013-02-18 | 2016-02-19 | 재단법인 대구테크노파크 | Composition for preventing, improving or treating allergic dermatitis comprising hot water extract or ferment extract of chestnut inner shell |
| KR101643048B1 (en) * | 2014-10-23 | 2016-07-27 | 단국대학교 천안캠퍼스 산학협력단 | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising castanea crenata inner shell extract |
| CN104770644A (en) * | 2015-04-29 | 2015-07-15 | 唐凯 | Diabetes health care product based on affinal drugs and diet |
| WO2018021476A1 (en) * | 2016-07-29 | 2018-02-01 | 株式会社 サティス製薬 | Chestnut-skin extract |
| CN107686451B (en) * | 2017-09-29 | 2020-07-03 | 烟台新时代健康产业日化有限公司 | Preparation method of chestnut skin extract containing ceramide |
| KR102165675B1 (en) | 2018-10-17 | 2020-10-14 | 강진영 | A cosmetic manufacturing method comprising an extract extracted from chestnuts or a peptide fraction isolated therefrom and natural caffeine derived from coffee |
| JP7263538B2 (en) * | 2019-11-01 | 2023-04-24 | 株式会社 資生堂 | Skin condition evaluation method using active PAR-2 in skin as index, screening method for PAR-2 activation promoter or inhibitor, and PAR-2 activation inhibitor |
| FR3124947A1 (en) * | 2021-07-12 | 2023-01-13 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Ingestible composition (Ci) for use in the treatment of a skin disorder induced by an intestinal disorder |
| KR20240149303A (en) | 2023-04-04 | 2024-10-14 | 연세대학교 산학협력단 | a novel compound derived from chestnut pericarp and composition for improving hair loss containing the compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09175993A (en) * | 1995-12-27 | 1997-07-08 | Pairei:Kk | Production of bathing agent |
| JPH10226633A (en) * | 1997-02-14 | 1998-08-25 | Koreana Cosmetics Co Ltd | Cosmetic composition containing extract of chestnut bur |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH092960A (en) * | 1995-06-15 | 1997-01-07 | Watanabesan Shoten:Kk | Dermatitis treating agent and treatment of dermatitis |
| JPH09182574A (en) * | 1996-01-05 | 1997-07-15 | Pairei:Kk | Production of chestnut tea |
| KR100308178B1 (en) * | 1997-11-10 | 2002-02-28 | 유상옥,송운한 | Skin wrinkle care composition containing chestnut bark extract |
| KR100376136B1 (en) * | 1998-08-13 | 2003-06-18 | 주식회사 코리아나화장품 | Astringent Cosmetic Composition Containing Yulpi Extract |
| KR20000065305A (en) * | 1999-04-01 | 2000-11-15 | 유상옥 | Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts |
| EP1226809B1 (en) * | 1999-10-29 | 2007-05-30 | Kyowa Hakko Kogyo Co., Ltd. | Skin texture-improving agents |
| KR20010092070A (en) * | 2000-03-20 | 2001-10-24 | 유상옥,송운한 | Skin elasticity-improving cosmetic composition comprising Chestnut inner bark extract and Malt extract |
| JP2002371276A (en) * | 2001-06-14 | 2002-12-26 | Kanebo Ltd | Antioxidant, food and cosmetic obtained by using the same |
| JP3847649B2 (en) * | 2002-04-01 | 2006-11-22 | 株式会社ノエビア | Topical skin preparation |
| KR100483539B1 (en) * | 2002-12-10 | 2005-04-18 | 이진형 | Composition for preventing or treating atopic dermatitis and process for preparation thereof |
| JP4090861B2 (en) * | 2002-12-13 | 2008-05-28 | クラシエフーズ株式会社 | Antioxidants, foods and cosmetics using the same |
| JP2005139070A (en) * | 2003-11-04 | 2005-06-02 | Kanebo Cosmetics Inc | Skin cosmetic |
| CN101268847A (en) * | 2007-03-23 | 2008-09-24 | 张宝林 | Blood cleaning cola for eliminating sub-health |
| KR20080090169A (en) * | 2007-04-04 | 2008-10-08 | (주) 아디포젠 | Active extracts, containing scoparone, isolated from mugwort or chestnut peel having inhibitory effects on obesity |
| JP2008195936A (en) * | 2008-01-28 | 2008-08-28 | Kracie Foods Ltd | Antioxidant and food and cosmetics using the same |
| KR20080101821A (en) * | 2008-08-27 | 2008-11-21 | 김선일 | Cosmetic included to flos |
| KR101172114B1 (en) * | 2008-11-17 | 2012-08-10 | (주)아모레퍼시픽 | Skin whitening cosmetic composition containing natural crop powders as exfoliation surface skin cells |
-
2010
- 2010-06-18 CN CN2010800359033A patent/CN102458156A/en active Pending
- 2010-06-18 CN CN201510750348.7A patent/CN105285986A/en active Pending
- 2010-06-18 WO PCT/KR2010/003983 patent/WO2010147440A2/en active Application Filing
- 2010-06-18 JP JP2012515997A patent/JP2012530699A/en active Pending
- 2010-06-18 KR KR1020117031657A patent/KR101338681B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09175993A (en) * | 1995-12-27 | 1997-07-08 | Pairei:Kk | Production of bathing agent |
| JPH10226633A (en) * | 1997-02-14 | 1998-08-25 | Koreana Cosmetics Co Ltd | Cosmetic composition containing extract of chestnut bur |
Non-Patent Citations (5)
| Title |
|---|
| MARTIN STEINHOFF: "Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin", 《THE JOURNAL OF NEUROSCIENCE》 * |
| TAKATSUGU KOJIMA ETAL: "Anti-allergic effect of apple polyphenol on patients with atopic dermatitis: A pilot study", 《ALLERGOLOGY INTERNATIONAL》 * |
| 何黎: "皮肤屏障与保湿", 《实用医院临床杂质》 * |
| 兰茂 等: "《滇南本草·第1卷》", 30 November 2008, 云南科技出版社 * |
| 方家选 等: "《南阳中药优质栽培技术》", 31 August 2004, 三秦出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120027432A (en) | 2012-03-21 |
| KR101338681B1 (en) | 2013-12-09 |
| WO2010147440A2 (en) | 2010-12-23 |
| JP2012530699A (en) | 2012-12-06 |
| WO2010147440A3 (en) | 2011-03-31 |
| CN102458156A (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105285986A (en) | Health food or pharmaceutical composition comprising chestnut shell extract | |
| RU2671492C2 (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders | |
| JP2001504463A (en) | Pharmaceutical composition containing Kukunoki nut oil | |
| KR20200042440A (en) | Parenteral non-systemic administration of buffers to inhibit solid tumors, hyperpigmentation and metastasis of gout | |
| AU2004251720A1 (en) | Method for treatment of sores and lesions of the skin | |
| US20230026847A1 (en) | Cbd formulations and uses thereof | |
| KR101510595B1 (en) | Composition comprising eugenol for preventing or treating atopic dermatitis | |
| JP2011512392A (en) | Medicine | |
| WO2013062424A1 (en) | Method and composition for the treatment of pain and/or inflammation | |
| KR20120027436A (en) | Cosmetic composition comprising chestnut shell extract | |
| KR20070054222A (en) | Medicine having analgesic effects | |
| EP3884942B1 (en) | Use of bulleyaconitine a for treating skin disorders | |
| KR20110125087A (en) | A composition comprising extract from herbal for improving pruritus | |
| KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| JP2003335688A (en) | Bradykinin receptor antagonist | |
| CN108619486B (en) | Ointment for treating skin diseases and preparation method thereof | |
| KR101470087B1 (en) | Composition for preventing or treating or improvingatopic dermatitis comprising immunosuppressant and transglutaminase 2 inhibitor | |
| WO2017043350A1 (en) | Anti-itching agent | |
| US11344505B1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| CN108096283B (en) | Application of polyrhachis vicina Roger extract in preparation of medicine for preventing and treating pruritus | |
| KR100860350B1 (en) | Cosmetic composition for prompting hair growth containing herb extraction | |
| CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
| KR101567735B1 (en) | Composition for preventing or improving or treating psoriasis comprising immunomodulating agent and glucosamine | |
| KR102248513B1 (en) | A composition for preventing and treating athlete's foot |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |
|
| RJ01 | Rejection of invention patent application after publication |